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	The	British	Thoracic	Society	(BTS)	Winter	Meeting	2017	attracted	2300	delegates	to	 London.	 The	 Meeting	 showcased	 the	 latest	 advances	 in	 respiratory	 science	including	clinical	and	translational	research.	This	article	summarises	selected	key	sessions.		
BTS/British	 Lung	 Foundation/British	 Association	 of	 Lung	 Research	 early	
career	investigators	symposium	
	This	exciting	session,	featuring	six	emerging	early-career	academics,	provided	a	glimpse	at	the	future	of	UK	academic	respiratory	medicine.	Dr	Wortley	(London,	UK)	 won	 the	 BTS	 award	 for	 his	 research	 which	 utilised	 in	 vivo	 and	 ex	 vivo	experimental	 approaches	 to	 demonstrate	 that	 bacteria	 can	 activate	 sensory	nerves,	 specifically	 via	 TLR-21.	 These	 effects	 could	 explain	 increased	 coughing	episodes	that	occur	during	acute	bacterial	infection.	Runner	up	for	this	award	was	Dr	Walstead	(London,	UK	and	Copenhagen,	Denmark)	who	presented	data	from	six	subjects	with	exercise-induced	laryngeal	obstruction	showing	that	respiratory	work	and	neural	drive	increases	in	close	association	with	paradoxical	laryngeal	closure	in	this	condition2.			Dr	Wood	(Cambridge,	UK)	was	awarded	the	British	Association	of	Lung	Research	prize	for	work	demonstrating	that	complement	protein	C5A	can	impair	neutrophil	phagocytosis	of	Staphyloccus	aureus	in	a	PI3-kinase	dependent	manner3,	raising	speculation	 that	 that	 these	 mechanisms	 could	 be	 manipulated	 to	 alter	susceptibility	to	nosocomial	infections.	The	runner	up	was	Dr	Bonvini	(London,	UK),	for	her	work	focussing	on	the	role	oestrogen	plays	in	airway	sensory	nerve	activation.	β-oestradiol	induced	depolarisation	of	isolated	guinea	pig	vagal	nerves	






Four	 notable	 studies	 published	 in	 Thorax	 were	 showcased	 at	 this	 year’s	symposium.	 Dr	 Jean-Michel	 Sallenave’s	 group	 (Paris,	 France)	 highlighted	 that	
Pseudomonas	 aeruginosa	 elastase	 LasB	 is	 a	 secreted	 virulence	 factor	 that	 can	downregulate	 CFTR	 and	 degrade	 anti-bacterial	 immune	 mediators	 IL-6	 and	Trappin-2,	 important	 epithelial	 derived	 antimicrobial	 factors6.	 Intranasal	administration	of	LasB	in	mice	also	induced	inflammation,	weight	loss	and	death,	effects	 that	 were	 rescued	 by	 overexpression	 of	 IL6	 and	 Trappin2.	 These	 data	suggest	 that	 targeting	 LasB	 could	 represent	 a	 novel	 therapeutic	 strategy	 for	patients	susceptible	to	Pseudomonas	infections	including	those	with	cystic	fibrosis	and	COPD.			Dr	 Lucile	 Sese	 (Bobigny,	 France)	 presented	 thought	 provoking	 data	 from	 a	prospective	 cohort	 study	 showing	 that	 acute	 exacerbations	 of	 idiopathic	pulmonary	fibrosis	(IPF)	are	significantly	temporally	associated	with	an	increase	in	 mean	 level	 of	 atmospheric	 ozone	 and	 that	 exposure	 to	 elevated	 levels	 of	particulate	matter	PM10	and	PM2.5	are	associated	with	increased	mortality	7.			Dr	 Andrey	 Zinchuk	 (New	 Haven,	 USA)	 presented	 a	 multi-centre	 observational	study	in	which	polysomnographic	data	was	used	to	characterise	novel	phenotypes	of	obstructive	sleep	apnoea	(OSA)8.	Subgroups	could	be	identified	that	captured	risk	of	adverse	cardiovascular	outcomes	otherwise	missed	by	conventional	OSA	severity	 classification	 criteria.	 These	 classification	 methods	 could	 have	 future	importance	for	risk	stratification	and	treatment	selection.			Dr	 Cecilia	 O’Kane	 (Belfast,	 Northern	 Ireland)	 used	 human	 in	 vivo	 and	 ex	 vivo	models	of	lipopolysaccharide-induced	inflammation	to	demonstrate	that	aspirin	could	 reduce	 pulmonary	 neutrophilia	 and	 neutrophil-mediated	 inflammation9.	These	 effects	 raise	 speculation	 that	 use	 of	 aspirin	 could	 be	 beneficial	 in	neutrophil-driven	 pulmonary	 inflammatory	 diseases	 such	 as	 acute	 respiratory	distress	syndrome	(ARDS).	
	
Plenary	Scientific	The	plenary	Scientific	session	showcases	some	of	the	brightest	rising	stars	of	UK	respiratory	academia.			Prof	David	Kiely	 (Sheffield,	UK)	emphasised	 the	 importance	of	 a	multimodality	approach	 to	 diagnosis	 and	 prognostication	 in	 pulmonary	 hypertension.	 The	potential	use	of	in	silico	approaches,	combined	with	computational	modelling	and	machine	learning,	to	classify	patients	could	reduce	future	need	for	invasive	tests.			Dr	 Charlotte	 Summers	 (Cambridge,	 UK)	 presented	 her	 work	 on	 neutrophil	biology.	Her	data,	which	included	some	fascinating	video	images,	indicated	that	neutrophil	transit	time	across	the	pulmonary	circulation	is	faster	than	previously	thought	 and	 that	 primed	 neutrophils	 are	 retained	 in	 the	 vasculature	 and	subsequently	deprime	and	are	re-released	into	the	systemic	circulation.	Defects	in	these	processes	may	underlie	development	of	ARDS.			Dr.	 Robert	 Snelgrove	 (London,	 UK)	 discussed	 his	 work	 into	 a	 novel	 anti-inflammatory	 pathway	 in	 which	 leukotriene	 A4	 hydrolase	 degrades	 an	
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extracellular	matrix-derived	neutrophil	chemoattractant	proline-glycine-proline	(PGP).	Using	a	mouse	model	of	allergic	airways	disease,	he	demonstrated	that	PGP	accumulation	 drove	 pathological	 epithelial	 remodelling,	 mucus	 production	and	airway	hyper-responsiveness.	 Subsequently,	 he	 demonstrated	 that	 PGP	 is	elevated	 in	the	sputum	of	patients	with	severe	asthma,	raising	speculation	that	this	could	provide	a	viable	future	therapeutic	target.			Finally,	Dr	John	Hurst	(London,	UK)	highlighted	the	importance	of	exacerbation	risk	in	COPD,	suggesting	that	an	episode	of	hospitalised	exacerbation	should	be	a	call	 to	 arms	 for	 healthcare	 professionals.	 He	 also	 discussed	 the	 importance	 of	disease	activity	in	COPD	and	raised	speculation	that	small	airway	imaging	could	provide	an	early	window	to	identify	active	disease	that	requires	intervention.		
	
The	Morriston	Davies	Lecture	The	Morriston	Davies	 lecture	was	given	by	Professor	 John	 Ioannidis	 (Stanford,	USA)	 and	 he	 proposed	 a	 controversial	 viewpoint	 that	 most	 published	 clinical	research	is	not	useful.	The	eight	criteria	of	clinically	useful	research	were	outlined	which	include:	problem	base,	context	placement,	information	gain,	pragmatism,	patient-centredness,	feasibility,	transparency	and	value	for	money.	Importantly,	most	 journals	 do	 not	 consider	 all	 8	 when	 assessing	 submitted	 manuscripts.	Professor	 Ioannidis	 additionally	 highlighted	 the	 importance	 of	 large	 scale	collaboration	and	adoption	of	replication	culture	(increased	focus	on	reproducible	science).		
The	BTS	Lecture	Professor	 Sir	 Michael	 Marmot	 (London,	 UK)	 gave	 a	 rousing	 lecture	 on	 health	inequalities	and	social	justice.	Describing	the	links	between	poverty	and	exposure	to	 pollution	 it	 becomes	 easy	 to	 understand	 the	 striking	 associations	 between	social	deprivation	and	lung	disease	across	the	UK.	Professor	Sir	Marmot	described	how	 improving	 education,	 housing	 and	 household	 pay	 could	 all	 have	 lasting	impacts	on	a	child’s	long-term	health.	In	doing	so,	he	created	a	compelling	case	for	social	transfer	(government	provided	social	assistance),	arguing	that,	without	it,	we	are	simply	treating	people	and	then	sending	them	back	to	the	conditions	that	made	them	unwell.			
Pulmonary	Vascular	Disease		Dr	 Luke	 Howard	 (London,	 UK)	 presented	 the	 new	 BTS	 outpatient	 pulmonary	embolism	(PE)	guidelines,	due	to	be	published	this	year.	Several	studies,	including	randomised	 controlled	 trials	 (RCTs)	 and	 meta	 analyses,	 have	 shown	 that	outpatient	management	 of	 low-risk	 patients	with	 confirmed	 PE	 is	 as	 safe	 and	effective	as	inpatient	care	10	11.	The	11-point	PESI	score	is	based	on	easily	obtained	clinical	data	and	is	the	most	widely	validated	risk	score	for	PE	(although	it	is	not	validated	for	use	in	pregnancy).		The	simplified	version	(s-PESI)	is	equally	able	to	identify	 patients	 at	 low-risk	 of	 mortality	 12.	 There	 is	 no	 value	 in	 adding	 BNP,	troponin	or	right	ventricular	(RV)	 function	assessments	to	 the	PESI/sPESI	as	 it	does	 not	 improve	 prediction	 of	 early	 mortality,	 which	 is	 key	 when	 deciding	between	outpatient	or	inpatient	care13	14.	First	line	treatment	for	confirmed	PE	is	
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either	a	direct	oral	anticoagulant	(DOAC)	or	initial	low	molecular	weight	heparin	(LMWH)	with	a	subsequent	switch	to	a	DOAC,	such	as	dabigatran	or	edoxaban.	There	are	no	data	yet	for	the	use	of	DOACs	in	cases	of	suspected	PE,	but	guidelines	suggest	 a	 DOAC	 could	 be	 used	 instead	 of	 LMWH	 whilst	 awaiting	 outpatient	imaging	(ideally	within	24	hours).				Dr	Gregory	Piazza	(Boston,	USA)	discussed	different	treatment	options	for	acute	PE.	 He	 highlighted	 that	 ultrasound-assisted	 catheter-directed	 thrombolysis,	which	 combines	 low-dose	 local	 fibrinolytics	and	mechanical	 clot	disruptioncan	rapidly	 improves	RV	 function	 in	 intermediate/high	 15	 and	 high-risk	 patients	 16	with	pulmonary	embolism.	In	contrast	to	the	2%	risk	of	intracranial	haemorrhage	associated	with	systemic	thrombolysis,	there	were	no	reports	of	this	complication	with	catheter-directed	therapy	17.	Furthermore,	lower	dose	(8mg	tPA)	and	shorter	duration	(2h)	therapy	was	recently	shown	to	be	as	effective	as	standard	catheter-directed	 regimens	 (24mg	 tPA	 over	 12-24	 hours)	 for	 submassive	 PE.	 In	 some	centres	 in	 the	 US,	 multidisciplinary	 PE	 teams	 have	 been	 founded	 to	 evaluate	patients	and	make	treatment	decisions18.	This	is	especially	useful	in	the	care	of	intermediate/high	risk	PE,	where	clinical	trial	data	and	guidelines	are	inadequate.	These	teams	consist	of	specialists	from	respiratory	medicine,	cardiology,	vascular	surgery,	radiology	and	haematology.	It	will	be	interesting	to	see	if	there	will	be	a	demand	for	this	type	of	service	in	the	NHS	in	the	future.			The	risk	of	PE	recurrence	is	significant,	even	in	patients	with	‘provoked’	PE		(25%	over	 10	 years).	 The	 EINSTEIN	 CHOICE	 study	 compared	 100mg	 aspirin	 to	prophylactic	and	treatment	doses	of	rivaroxaban	for	prevention	of	further	VTE	in	patients	with	unprovoked	and	provoked	PE.	 	Rivaroxaban	 reduced	 the	 relative	risk	of	VTE	by	70%	(20mg)	and	60%	(10mg)	compared	with	aspirin	at	1	year,	which	raises	the	question	of	whether	we	should	be	considering	long-term	anti-coagulation	in	all	patients.	19			
Interstitial	lung	disease	Patients	with	sporadic	 IPF	have	shorter	 telomeres	compared	with	age-matched	controls	and	mutations	in	telomerase	genes	have	been	identified	in	patients	with	familial	 IPF,	 implicating	 telomere	 dysfunction	 in	 the	 pathogenesis	 of	 IPF	 20	 21.	Professor	Paul	Wolters	(San	Francisco,	USA)	showed	that	deletion	of	the	telomere	shelterin	protein	TRF1	in	alveolar	epithelial	cells	(AECs)	leads	to	the	spontaneous	development	 of	 lung	 fibrosis	 in	 mice,	 suggesting	 that	 telomere	 dysfunction	 in	AECs	contributes	directly	to	the	development	of	lung	fibrosis22.	He	explained	that	the	telomere	 link	may	extend	beyond	IPF	and	predispose	to	other	 fibrotic	 lung	diseases.	Mutations	in	telomere	genes	have	been	identified	in	12%	of	patients	with	rheumatoid	 arthritis-	 associated	 ILD	 	 	 patients	 23	 and	 telomere	 length	 also	correlates	with	survival	in	chronic	hypersensitivity	pneumonitis	24.			Dr	Philip	Molyneaux	(London,	UK)	argued	that	infection	could	be	the	cause	of	IPF	given	that	previous	studies	have	shown	that	immunosuppressing	patients	with	is	harmful25.		Until	recently,	the	lungs	were	thought	to	be	sterile	but	thanks	to	new	culture-independent	 techniques	 we	 now	 recognise	 that	 the	 lungs	 of	 healthy	individuals	 harbour	 diverse	 bacterial	 populations.	 Patients	 with	 IPF	 have	 an	
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increased	bacterial	burden	in	bronchoalveolar	lavage	(BAL)	samples	compared	to	healthy	controls	and	COPD	patients.	In	patients	with	IPF	bacterial	load	at	the	time	of	 diagnosis	 correlates	 with	 survival26	 27.	 Interestingly,	 during	 acute	exacerbations,	 there	 is	 a	 further	 increased	 in	 bacterial	 burden	 and	 significant	change	in	the	profile	of	the	microbiome,	which	is	not	detected	by	routine	culture28.	The	 results	 of	 two	 ongoing	 studies	 examining	 the	 effect	 of	 antibiotics	 on	 IPF	outcome	(TIPAC	2	and	CleanUp	IPF)	are	eagerly	awaited.		Professor	 Martin	 Kolb	 (McMaster,	 Canada)	 presented	 the	 hypothesis	 that	mechanical	stretch	associated	with	breathing	contributes	to	disease	progression	in	IPF	29.	Stretching	stiff	fibrotic	lung	tissue	leads	to	the	release	and	activation	of	the	pro-fibrotic	cytokine,	TGF-β,	which	is	embedded	in	the	matrix.	30	This	occurs	at	 much	 lower	 levels	 in	 normal	 compliant	 lung.	 Enhanced	 TGF-β	 activation	contributes	to	deposition	of	further	matrix	proteins,	leading	to	stiffer	lungs	and	a	detrimental	feed-forward	loop.	This	could	explain	why	fibrosis	has	a	propensity	to	develop	 in	 the	 subpleural	 regions	where	 the	pressure	 change	and	stretch	 is	greatest.			Dr	Billy	Fahy	(Stevenage,	UK)	explained	that,	in	the	future,	biomarkers	could	be	used	 to	 differentiate	 subsets	 of	 IPF	 patients	 and	 guide	 therapeutic	 decisions.	However,	 there	are	no	biomarkers	currently	 in	clinical	use.	He	spoke	about	 the	challenges	of	biomarker	identification	and	how	machine	learning	is	being	used	to	identify	biomarker	signatures	in	large	datasets.	Using	data	from	the	longitudinal	cohort	PROFILE	study,	an	epithelial	biomarker	signature	was	recently	shown	to	predict	disease	progression	and	death	in	IPF31.			While	IPF	grabbed	a	lot	of	the	headlines,	we	also	heard	from	Dr	Vijay	Maharajan	(Cambridge,	 UK)	 who	 described	 ways	 to	 automate	 the	 analysis	 of	 cystic	 lung	disease.	 Splitting	 the	 lung	 into	 zones	 could	 allow	 accurate	 scoring	 of	 cyst	distribution	 and	 differentiate	 between	 diseases.	 The	 automated	 counting	 and	assessment	could	also	play	a	role	in	long-term	follow	up	and	clinical	trial	design.			
Asthma	Professor	Maria	Belvisi	(London,	UK)	focussed	on	the	non-allergic	influences	on	asthma.	Many	 non-allergic	 asthma	 triggers,	 such	 as	 pollution	 and	 tobacco,	 can	cause	 cough	 and	 breathlessness,	 symptoms	 that	 are	 largely	 unresponsive	 to	current	 treatments	 targeting	 inflammation.	 She	 hypothesised	 that	 irritants	directly	activate	Transient	Receptor	Potential	(TRP)	ion	channels	to	initiate	these	sensory	reflex	events.	She	highlighted	that	TRPV4	activation	releases	ATP,	which	in	 turn	acts	on	P2X3	present	on	sensory	nerves,	resulting	 in	 the	cough	reflex32.	The	discovery	of	this	axis	opens	up	a	completely	new	therapeutic	opportunity	for	improving	symptoms	with	use	of	either	P2X3	or	TRPV4	antagonists33.		Professor	 Adnan	 Custovic	 (London,	 UK)	 showed	 that	 the	 effect	 of	 early-life	exposures	(e.g.	to	cat)	on	sensitization	and	asthma	differs	over	time,	rendering	the	generalization	of	effects	 from	cross-sectional	analyses	misleading	34.	Therefore,	the	 findings	of	 apparently	 contradictory	 cross-sectional	 studies	may	 be	 due	 to	markedly	different	trajectories	of	clinical	outcomes	between	individuals	exposed	or	not	exposed	in	early	life	34.	He	showed	that	mite	allergen	avoidance	in	children,	
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using	allergen-proof	bedding,	reduces	emergency	hospital	attendance	with	severe	asthma	exacerbations	35	and	that	temperature-controlled	laminar	airflow	(TLA)	devices	in	real-life	studies	reduces	asthma	exacerbation	rates.	36	This	raises	the	question	 of	 whether	 asthma	 guidelines	 should	 reassess	 the	 role	 of	 allergen	avoidance	as	a	treatment	option.	More	controversially,	he	challenged	the	dogma	that	 allergen	 desensitisation	 is	 ineffective	 in	 asthma	 control.	 Sub-lingual	immunotherapy	 (SLIT)	 is	 certainly	 safe,	 and	 there	 is	 an	 increasing	 body	 of	evidence	that	dust	mite	SLIT	tablet	may	be	clinical	effective	in	adults	with	partially	controlled	allergic	asthma	37.	Grass	SLIT	tablet	may	also	modify	the	natural	history	of	airway	symptoms	in	grass-allergic	children	38		Professor	Liam	Heaney	(Belfast,	Northern	Ireland)	described	the	progress	on	the	UK	MRC	RASP	programme	on	severe	asthma	39.	The	aim	of	this	programme	is	to	understand	 disease	 control	 using	 composite	 endpoints,	 and	 by	 assessing	 drug	adherence	 using	 FeNO	 and	 the	 inhaler	 compliance	 assessment	 (INCA)	 device..	This	could	enable	the	down-titration	of	medication	where	feasible.	He	described	the	wide	range	of	novel	biologics	competing	for	a	narrow	market	although	with	potentially	major	health	economic	benefits	through	exacerbation	reduction.		Dr	 Stephen	 Fowler	 (Manchester,	 UK)	 contrasted	 and	 compared	 the	 BTS/SIGN	guidelines	with	new	NICE	asthma	guidelines.	There	 is	some	agreement,	but	 the	NICE	 guideline	 uses	 FeNO	 as	 part	 of	 an	 un-validated	 complex	 web-based	diagnostic	pathway	and	does	not	take	into	account	the	age	and	gender	differences	in	the	FeNO	normal	range.	In	addition,	NICE	guidance	does	not	include	important	topics	 such	 as	 smoking,	 co-morbidities,	 devices	 or	 pregnancy.	 There	 was	agreement	that	both	guidelines	were	based	on	efficacy	RCTs	in	unrepresentative	populations.	We	 therefore	 urgently	 need	 clinical	 effectiveness	 data	 in	 broader	populations	on	which	to	base	future	guidelines.		
COPD	Mechanistic	 aspects	 of	 COPD	 were	 focussed	 on	 at	 this	 year’s	 meeting	 with	intriguing	data	from	Lodge	et	al40	(Cambridge	UK)	showing	that	hypoxia	increases	neutrophil	 elastase	 in	 a	 PI3-kinase-dependent	manner,	 effects	 that	 are	 further	augmented	 during	 exacerbations.	 Evaluation	 of	 the	 neutrophil	 secretome	 in	hypoxic	conditions	showed	several	upregulated	proteins	that	may	contribute	to	tissue	damage.	These	proteins	could	represent	future	therapeutic	targets.	Ryan	et	
al	(Edinburgh,	UK)	highlighted	mechanisms	of	impaired	macrophage	efferocytosis	in	COPD.	Sulforaphane	an	agonist	of	the	transcription	factor	Nrf2	(which	regulates	antioxidant-response-elements)	 was	 shown	 to	 partially	 rescue	 defective	efferocytosis	in	monocyte	derived-	and	alveolar	macrophages	from	patients	with	COPD41.		Gillpin	(Belfast,	Northern	Ireland)	et	al	presented	work	looking	at	the	effects	of	cigarette	smoke	and	electronic	cigarette	vapour	extracts	on	growth	and	biofilm	formation	of	COPD	relevant	bacteria	including	H.	influenzae	and	P.	aeruginosa	in	




Infection	Dr	Abubakar	(London,	UK)	et	al	presented	data	from	PREDICT,	a	large	UK	multi-centre	study43.	In	this	study,	subjects	who	were	new	migrants	or	contacts	of	active	TB	cases	were	 screened	 for	 latent	TB.	There	were	97	out	of	9610	participants	(1%)	who	developed	active	TB	during	the	study.			The	authors	identified	that	using	either	interferon-gamma	release	assay	(IGRA)	based	tests	or	tuberculin	skin	test	with	a	15mm	threshold	were	best	suited	to	screening	in	low-risk	populations.		Dr	Szylar	(London,	UK)	et	al	evaluated	the	effects	of	regulatory	T	cells	(Tregs)	on	macrophage	inflammatory	responses	to	S.pneumoniae44.	Co-culture	of	monocyte	derived	macrophages	(MDM)	with	Tregs	reduced	MDM	production	of	TNF-α	and	IL-6.	They	also	demonstrated,	using	a	novel	human	in	vivo	model	of	pneumococcal	challenge	 involving	 intradermal	 injection	of	UV-killed	S.pneumoniae,	 that	Tregs	accumulate	at	the	site	of	injection.	These	preliminary	findings	suggest	Tregs	could	be	 important	 in	 modulating	 	 macrophage	 inflammatory	 responses	 to	
S.pneumoniae.	
	Dr	 Plowright	 (Nottingham,	 UK)	 evaluated	 outcomes	 following	 cardiovascular	events	in	a	large	cohort	of	101,597	patients	with	bronchiectasis45.	After	adjusting	for	age	and	sex,	there	was	no	difference	in	in-hospital	mortality	following	acute	myocardial	infarction,	coronary	artery	bypass	graft	or	percutaneous	angioplasty	in	 individuals	 with	 bronchiectasis	 compared	with	 the	 general	 population.	 The	presence	of	bronchiectasis	was,	however,	associated	with	 longer	mean	hospital	stay.	
	
Smoking		Dr	 Sanjay	 Agrawal	 (Leicester,	 UK)	 argued	 that	 there	 is	 no	 strong	 evidence	 to	suggest	that	that	cigarette	smokers	who	use	use	e-cigarettes	are	less	likely	to	quit	smoking.	Recent	data	suggests	that	vaping	does	increase	the	success	of	quit	rates	46.	 E-cigarettes	 are	 generally	 thought	 to	 be	 a	 safer	 alternative	 to	 smoking	traditional	cigarettes,	but	little	is	known	about	the	long-term	effects	of	vaping	on	lung	health.			There	are	>7000	different	flavours	of	e-liquids	available	in	the	US,	all	with	very	different	 chemical	 compositions.	There	 is	no	 regulation	or	 inhalational	 toxicity	testing	 performed	 prior	 to	 their	 release	 onto	 the	market,	 which	 is	 a	 cause	 for	concern.		Dr	Robert	Tarran	(North	Carolina,	USA)	showed	data	demonstrating	the	toxic	 effects	 of	 different	 flavour	 e-liquids	 on	 human	 airway	 epithelial	 cells	 in	
vitro47.	Examination	of	sputum	from	healthy	smokers	and	vapers	demonstrates	raised	levels	of	proteases	and	mucins	compared	with	controls,	which	raises	the	possibility	 that	 vaping	 could	 also	 cause	 emphysema48.	 He	 also	 showed	bronchoscopic	images	indicating	marked	erythema	in	the	airways	of	e-cigarette	users.	He	suggested	this	may	be	due	to	direct	heat	damage	from	e-cigarettes,	but	further	studies	are	required	to	investigate	this.			Dr	 Rachel	 Murray	 (Nottingham,	 UK)	 described	 the	 challenges	 to	 successfully	implementing	 smoking	 cessation	 in	 the	 NHS.	 In	 2015/2016	 475,000	 hospital	
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admissions	were	 directly	 smoking-related.	Moreover,	 even	 greater	 numbers	 of	current	 smokers	 are	 admitted	 to	 hospital	 every	 year	 (1.1	 million	 smokers	 in	2010/11).	 This	 represents	 a	 huge	 number	 of	 opportunities	 to	 intervene	 and	promote	 smoking	 cessation.	 Smoking	 cessation	 interventions	 are	 the	 most	effective	 method	 available,	 but	 Stop	 Smoking	 Services	 have	 been	 badly	 hit	 by	funding	cuts	49	.	Dr	Murray	argued	that,	although	NICE	guidance	and	Department	of	 Health	 policy	 outline	 key	 interventions	 for	 smoking	 cessation,	 without	regulatory	drivers	there	is	no	incentive	for	Trusts	to	deliver.				
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